0001636050-23-000008.txt : 20230214 0001636050-23-000008.hdr.sgml : 20230214 20230214070144 ACCESSION NUMBER: 0001636050-23-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sio Gene Therapies Inc. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853863315 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 23622227 BUSINESS ADDRESS: STREET 1: 1501 BROADWAY STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 877-746-4891 MAIL ADDRESS: STREET 1: 1501 BROADWAY STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Gene Therapies Ltd. DATE OF NAME CHANGE: 20190516 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 8-K 1 siox-20230214.htm 8-K siox-20230214
false000163605000016360502023-02-142023-02-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 14, 2023
Sio Gene Therapies Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37418
85-3863315
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1501 Broadway
12th Floor
New York, New York 10036

(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code): +1 646 677 6770
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
SIOX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02    Results of Operations and Financial Condition.

On February 14, 2023, Sio Gene Therapies Inc. (the "Registrant") issued a press release announcing its financial results for the three and nine months ended December 31, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number
Description of Document
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIO GENE THERAPIES INC.
Dated:
February 14, 2023
By:
/s/ David Nassif
Name:
David Nassif
Title:
Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel


EX-99.1 2 siox8-k02142023exx991.htm EX-99.1 Document


Exhibit 99.1
sioxa.jpg

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively
Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period
$46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval

NEW YORK, NY, February 14, 2023 (GLOBE NEWSWIRE) – Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.

“Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination of the licenses to our three clinical-stage programs, the significant workforce reduction initiated last year April and successful negotiations with vendors and landlords. We are now focused on taking the steps necessary to put the Company and its three subsidiaries into the liquidation and dissolution process, including a stockholder vote expected to be held in April,” said David Nassif, J.D., Chief Executive Officer of Sio Gene Therapies.

Fiscal Third Quarter Financial Summary

Research and development expenses were $1.9 million for the three months ended December 31, 2022 and $21.3 million for the three months ended December 31, 2021. The $19.4 million decrease was primarily related to decreases in:

(i) program-specific costs relating to our prior AXO-Lenti-PD and AXO-AAV-GM1 and AXO-AAV-GM2 programs, which decreased $15.5 million as we wound down our clinical-stage programs subsequent to our termination of the Oxford Biomedica and UMass agreements; and

(ii) unallocated internal costs, which decreased $3.9 million primarily due to reductions in personnel-related costs after announcing the discontinuation of our clinical-stage programs and initiating a significant reduction in workforce in April 2022.

General and administrative expenses were $2.6 million for the three months ended December 31, 2022 and $4.1 million for the three months ended December 31, 2021. The decrease of $1.5 million was primarily due to decreases of $1.0 million in stock-based compensation expense, $0.4 million of which results from prior year expense associated with Roivant Sciences Ltd. ("RSL") equity instruments held by our former Chief Executive Officer, and $0.6 million in personnel-related expenses related to the workforce reduction that commenced in April 2022.

The net loss for the fiscal third quarter ended December 31, 2022 was $4.0 million, or $0.05 per share, compared to a net loss of $25.5 million, or $0.35 per share, in the fiscal third quarter ended December 31, 2021.

As of December 31, 2022, we had $46.13 million of cash and cash equivalents. We hold no short-term or long-term debt on the balance sheet.

Fiscal Nine Months Financial Summary

Research and development expenses were $7.8 million for the nine months ended December 31, 2022 and $40.8 million for the nine months ended December 31, 2021. The $33.0 million decrease was primarily related to decreases in:

(i) program-specific costs relating to our prior AXO-Lenti-PD and AXO-AAV-GM1 and AXO-AAV-GM2 programs, which decreased $24.6 million as we wound down our clinical-stage programs subsequent to our termination of the Oxford Agreement and the UMMS Agreement; and

1



(ii) unallocated internal costs, which decreased $8.4 million primarily due to reductions in personnel-related costs after announcing the discontinuation of our clinical-stage programs and initiating a significant reduction in workforce in April 2022. Personnel-related costs incurred during the nine months ended December 31, 2022 included $0.7 million of severance expense. Other costs incurred during the nine months ended December 31, 2022 included $0.7 million related to the early termination of the laboratory space lease in Durham, North Carolina and $0.6 million of losses on sales of equipment and furniture related to the termination of that lease. Further, stock-based compensation expense incurred during the nine months ended December 31, 2022 benefited from the reversal of $0.4 million from prior periods resulting from the workforce reduction.

General and administrative expenses were $8.5 million for the nine months ended December 31, 2022 and $17.7 million for the nine months ended December 31, 2021. The decrease of $9.2 million was primarily due to a decrease of $8.3 million in stock-based compensation expense, $6.3 million of which results from prior year expense associated with RSL equity instruments held by our former Chief Executive Officer, and a decrease of $1.7 million in personnel-related expenses.

The net loss for the nine months ended December 31, 2022 was $15.5 million, or $0.21 per share, compared to a net loss of $58.6 million, or $0.80 per share, for the nine months ended December 31, 2021.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "expect," "estimate," "may" and other similar expressions are intended to identify forward-looking statements. For example, all statements Sio makes regarding the proposed dissolution and its timing, including for holding a special stockholder meeting to approve the dissolution, cash position to support the dissolution, costs associated with its operating activities, potential cost savings and other benefits from cost reduction activities, and funding requirements and/or cash burn runway are forward-looking. All forward-looking statements are based on estimates and assumptions by Sio’s management that, although Sio believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Sio expected. Such risks and uncertainties include, among others, the
availability, timing and amount of liquidating distributions; the amounts that will need to be set aside by Sio; the adequacy of such reserves to satisfy Sio’s obligations; potential unknown contingencies or liabilities, including tax claims, and Sio’s ability to favorably resolve them or at all; the amount of proceeds that might be realized from the sale or other disposition of any remaining assets; the application of, and any changes in, applicable tax laws, regulations, administrative practices, principles and interpretations; the incurrence by Sio of expenses relating to the dissolution; the ability of the board of directors to abandon, modify or delay implementation of the dissolution, even after stockholder approval; the uncertain macroeconomic environment; continuing impact of the COVID-19 pandemic on Sio’s operations; the actual funds required for planned operating activities; costs, risks and timing related to headcount reductions and capital conservation plans; and the outcome of interactions with regulatory agencies. These statements are also subject to a number of material risks and uncertainties that are described in Sio’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Sio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT

In connection with the proposed dissolution, the Company has filed with the SEC a preliminary proxy statement and other relevant materials and will file a definitive proxy statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PLAN OF DISSOLUTION AND RELATED MATTERS OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT SIO GENE THERAPIES, INC., THE PROPOSED DISSOLUTION AND RELATED MATTERS. Stockholders may obtain a free copy of the proxy statement and the other relevant materials (when they become available), and any other documents filed by the Company with the SEC, at the SEC's website at http://www.sec.gov or on the "Investors" section of Sio’s website at www.siogtx.com.

Participants in the Solicitation

Sio and its executive officer and directors may be deemed to be participants in the solicitation of proxies from its stockholders with respect to the proposed dissolution and related matters and any other matters to be voted on at the special meeting of stockholders. Information regarding the names, affiliations and interests of such directors and executive officer will be included in the proxy statement (when available). Additional information regarding such directors and executive officer is included in Sio’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022, which was filed with the SEC on June 14, 2022.

2



Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Sio’s shareholders in connection with the dissolution and related matters and any other matters to be voted upon at the special meeting will be set forth in the proxy statement (when available). These documents are available free of charge as described in the preceding section.


Contacts:

Media, Investors and Analysts

David W. Nassif
Sio Gene Therapies Inc.
Chief Executive Officer, Chief Financial Officer and General Counsel
david.nassif@siogtx.com
3



SIO GENE THERAPIES INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share amounts)

 Three Months Ended December 31,Nine Months Ended December 31,
 2022202120222021
Operating expenses:
Research and development expenses
(includes stock-based compensation expense (benefit) of $0 and $130 for the three months ended December 31, 2022 and 2021 and $(409) and $1,051 for the nine months ended December 31, 2022 and 2021, respectively)
$1,883 $21,287 $7,761 $40,793 
General and administrative expenses
(includes stock-based compensation expense of $227 and $1,268 for the three months ended December 31, 2022 and 2021 and $692 and $8,966 for the nine months ended December 31, 2022 and 2021, respectively)
2,600 4,086 8,533 17,693 
Total operating expenses4,483 25,373 16,294 58,486 
Other (income) expenses:
Other (income) expense, net(464)83 (785)105 
Loss before income tax benefit(4,019)(25,456)(15,509)(58,591)
Income tax benefit— — (4)(28)
Net loss $(4,019)$(25,456)$(15,505)$(58,563)
Net loss per share of common stock — basic and diluted$(0.05)$(0.35)$(0.21)$(0.80)
Weighted-average shares of common stock outstanding — basic and diluted73,975,196 73,335,279 73,905,737 73,046,889 
4



SIO GENE THERAPIES INC.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share amounts)

December 31, 2022March 31, 2022
Assets 
Current assets:  
Cash and cash equivalents$46,127 $63,729 
Restricted cash— 1,184 
Prepaid expenses and other current assets789 5,214 
Income tax receivable356 1,609 
Total current assets47,272 71,736 
Operating lease right-of-use assets— 2,444 
Property and equipment, net— 900 
Total assets$47,272 $75,080 
Liabilities and Stockholders’ Equity   
Current liabilities:  
Accounts payable$201 $3,984 
Accrued expenses1,951 8,232 
Current portion of operating lease liabilities— 786 
Total current liabilities2,152 13,002 
Operating lease liabilities, net of current portion— 1,730 
Total liabilities2,152 14,732 
Stockholders’ equity:  
Common stock, par value $0.00001 per share, 1,000,000,000 shares authorized, 73,975,196 and 73,739,378 issued and outstanding at December 31, 2022 and March 31, 2022, respectively
Additional paid-in capital923,249 922,966 
Accumulated deficit(878,461)(862,956)
Accumulated other comprehensive income 331 337 
Total stockholders’ equity 45,120 60,348 
Total liabilities and stockholders’ equity $47,272 $75,080 
















5



SIO GENE THERAPIES INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Nine Months Ended December 31,
20222021
Cash flows from operating activities: 
Net loss$(15,505)$(58,563)
Adjustments to reconcile net loss to net cash used in operating activities: 
Non-cash lease expenses2,444 229 
Stock-based compensation expense283 10,017 
Depreciation and non-cash amortization137 187 
Change in operating lease liabilities(2,516)(265)
Other857 
Changes in operating assets and liabilities: 
Prepaid expenses and other current assets4,425 2,104 
Income tax receivable1,253 (76)
Accounts payable(3,783)5,270 
Accrued expenses(6,281)(1,434)
Net cash used in operating activities(18,686)(42,524)
Cash flows from investing activities: 
Cash proceeds from sale of long-term investment— 4,343 
Cash proceeds from sale of property and equipment190 — 
Purchases of property and equipment(290)(336)
Net cash (used in) provided by investing activities(100)4,007 
Cash flows from financing activities: 
Cash proceeds from issuance of shares of common stock, net of issuance costs— 1,441 
Net cash provided by financing activities— 1,441 
Net change in cash and cash equivalents, restricted cash and long-term restricted cash(18,786)(37,076)
Total cash and cash equivalents, restricted cash and long-term restricted cash—beginning of period64,913 120,170 
Total cash and cash equivalents, restricted cash and long-term restricted cash—end of period$46,127 $83,094 
Cash and cash equivalents —beginning of period63,729 118,986 
Restricted cash included in current assets—beginning of period1,184 — 
Restricted cash included in long-term assets—beginning of period— 1,184 
Total cash and cash equivalents, restricted cash and long-term restricted cash—beginning of period$64,913 $120,170 
Cash and cash equivalents—end of period46,127 81,910 
Restricted cash included in current assets—end of period— 1,184 
Total cash and cash equivalents and restricted cash—end of period$46,127 $83,094 
6
EX-101.SCH 3 siox-20230214.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 siox-20230214_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 siox-20230214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Entity Addresses [Line Items] Entity Addresses [Line Items] Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material Address Type [Domain] Address Type [Domain] City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Cover [Abstract] Cover [Abstract] Entity Addresses [Table] Entity Addresses [Table] Pre-commencement Tender Offer Pre-commencement Tender Offer Country Region Country Region Amendment Flag Amendment Flag Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Document Type Document Type Entity Registrant Name Entity Registrant Name Former Address Former Address [Member] Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 siox-20230214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 sioxa.jpg begin 644 sioxa.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page
Feb. 14, 2023
Entity Addresses [Line Items]  
Document Type 8-K
Document Period End Date Feb. 14, 2023
Entity Registrant Name Sio Gene Therapies Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37418
Entity Tax Identification Number 85-3863315
Entity Address, Address Line One 1501 Broadway
Entity Address, Address Line Two 12th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
Country Region 1
City Area Code 646
Local Phone Number 677 6770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol SIOX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001636050
XML 9 siox-20230214_htm.xml IDEA: XBRL DOCUMENT 0001636050 2023-02-14 2023-02-14 false 0001636050 8-K 2023-02-14 Sio Gene Therapies Inc. DE 001-37418 85-3863315 1501 Broadway 12th Floor New York NY 10036 1 646 677 6770 false false false false Common Stock, par value $0.00001 per share SIOX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://siogtx.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports siox-20230214.htm siox-20230214.xsd siox-20230214_def.xml siox-20230214_lab.xml siox-20230214_pre.xml siox8-k02142023exx991.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "siox-20230214.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 24 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "siox-20230214_def.xml" ] }, "inline": { "local": [ "siox-20230214.htm" ] }, "labelLink": { "local": [ "siox-20230214_lab.xml" ] }, "presentationLink": { "local": [ "siox-20230214_pre.xml" ] }, "schema": { "local": [ "siox-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "siox", "nsuri": "http://siogtx.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "siox-20230214.htm", "contextRef": "i2e8b4f37bed141f0b340c4abb72b82f8_D20230214-20230214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://siogtx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "siox-20230214.htm", "contextRef": "i2e8b4f37bed141f0b340c4abb72b82f8_D20230214-20230214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://siogtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001636050-23-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001636050-23-000008-xbrl.zip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end